Business Context and Reporting Period
This Form 8-K filing by Labcorp Holdings Inc. reports a corporate governance event dated December 9, 2025. The filing was signed on December 15, 2025, by Sandra D. van der Vaart, Executive Vice President, Chief Legal Officer, and Corporate Secretary.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the announced departure of a senior executive:
- Mark Schroeder, Executive Vice President and President of Diagnostics Laboratories and Chief Operations Officer, has notified the Company of his intention to retire.
- The retirement is effective April 1, 2026.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors related to the departure. No unusual items or contingencies were disclosed in this text.
Investor Verification Checklist
- Confirm the timeline for the transition of duties for the Diagnostics Laboratories division and Chief Operations Officer role.
- Verify if a successor has been identified or if an interim appointment will be made prior to April 1, 2026.
- Review subsequent filings for any changes to the executive compensation plan or severance arrangements associated with Mr. Schroeder's retirement.